AI assistant
Protagonist Therapeutics, Inc — Director's Dealing 2024
Mar 2, 2024
31163_dirs_2024-03-01_8dbc5598-a02e-4d7a-ada8-feb3c5b0ee01.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Protagonist Therapeutics, Inc (PTGX)
CIK: 0001377121
Period of Report: 2024-03-01
Reporting Person: Waddill William D. (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-03-01 | Common Stock | M | 12975 | $6.09 | Acquired | 24975 | Direct |
| 2024-03-01 | Common Stock | S | 12975 | $31.34 | Disposed | 12000 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-03-01 | Stock Option (right to buy) | $6.09 | M | 12975 | Disposed | 2026-07-16 | Common Stock (12975) | Direct |
Footnotes
F1: Sale of shares effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 10, 2023.
F2: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $30.46 to $31.99. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3: These stock options are fully vested.